-
06-08-2020, 09:24 AM
#571
Member
Originally Posted by whatsup
All third world countries, ask yourself why is that ?
Yawn, go troll somewhere else.
-
25-08-2020, 12:27 PM
#572
Member
TRU are going great since the capital raising at 5 cents recently. Over 9 cents currently with plenty of upside from here. One of my better recent investments !
-
26-08-2020, 06:40 AM
#573
Member
Still believe it will move like PEB. =D
-
26-08-2020, 06:58 AM
#574
im thinking its more likely to move like BGI , CBD
-
04-09-2020, 10:09 PM
#575
Originally Posted by jimdog31
im thinking its more likely to move like BGI , CBD
I think so too. In part because Sharesies buyers have been talking about TRU. They love the penny stocks
-
06-09-2020, 08:57 AM
#576
Member
Going to test previous high at 0.30? The market cap will only be $100mil, still very cheap compare to PEB...
-
06-09-2020, 12:50 PM
#577
Member
After the share issue/dilution, the previous high equates to 0.175 cents. They did issue a heap of shares. Need some results to get to a price lift, maybe those crazies at sharesies will send it there regardless. What’s up will be most upset.
Looking forward to AGM this week.
-
06-09-2020, 12:51 PM
#578
-
07-09-2020, 11:50 AM
#579
Member
This Feb 2020 research paper from Turkey found that Truscreening is more accurate than pap-testing but not cost effective yet.
ABSTRACT Background: Although extensive screening methods had been developed, cervical cancer remains to be an essential health problem. Early detection and administration of appropriate therapy is still a lifesaving procedure, especially for cervical cancer. The most common screening method for cervical cancer is still the cervical cytology (Pap-test). We aim to find out the advantages and disadvantages of a recently developed method, which is called as TruScreen.
Methods: Two different approaches had been used (conventional Pap test and TruScreen), and 1438 patients were included in the study. Of these, 819 had been screened with TruScreen. All eligible patients were firstly screened using TruScreen and then using the Pap-test. Each patient with an abnormal TruScreen result was referred to colposcopy room, where she was re-evaluated using colposcopy.
Results: A total of 819 patients underwent TruScreen, and the results were abnormal in 261 patients and normal in 558 patients Interception rates for cervical dysplasia with TruScreen have been found to be better than the conventional Pap test. The need for colposcopy dramatically increased with the use of TruScreen. Use of TruScreen alone was not found to be cost effective.
Conclusions: Combination with other methods of screening would decrease the cost of the process. Further studies needed to find out the possible effects for the combination of TruScreen with other testing methods.
https://www.researchgate.net/publica...prob_TruScreen
-
07-09-2020, 03:52 PM
#580
Junior Member
13 August 2020
MARKET RELEASE
TRUSCREEN LIMITED (“TRU”) – CHANGE OF NAME
TRU has resolved to change its name from “Truscreen Limited” to “Truscreen Group Limited” with legal effect from 21 August 2020. The change is scheduled to be effective on NZX’s systems from 21 August 2020
The change of name is required as part of the ASX dual listing process to distinguish it clearly from its Australian subsidiary company Truscreen Pty Limited.
I am quite confused on the last part, does this mean that they are planning to list on ASX? Although they are on net loss and may not meet the listing requirement...
Tags for this Thread
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
-
Forum Rules
|
|
Bookmarks